Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide

This publication has 54 references indexed in Scilit:

• COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer
  Nucleic Acids Research, 2009
• Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression
  Molecular and Cellular Biochemistry, 2009
• Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
  Journal of Thoracic Oncology, 2009
• A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
  British Journal of Cancer, 2009
• Isoform-selective histone deacetylase inhibitors
  Chemical Society Reviews, 2008
• Histone Deacetylase Inhibitor Depsipeptide Activates Silenced Genes through Decreasing both CpG and H3K9 Methylation on the Promoter
  Molecular and Cellular Biology, 2008
• Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases
  Applied Microbiology and Biotechnology, 2007
• Anticancer activities of histone deacetylase inhibitors
  Nature Reviews Drug Discovery, 2006
• Targeting histone deacetylase in cancer therapy
  Medicinal Research Reviews, 2006
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004